Journal of Clinical Endocrinology & Metabolism, Vol 41, 373-379, Copyright © 1975 by Endocrine Society

ARTICLES

Disposition of a new, nonsteroid, antiandrogen, alpha,alpha,alpha- trifluoro-2-methyl-4'-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose

B Katchen and S Buxbaum

A single oral 200 mg dose of tritium-labeled alpha,alpha,alpha- trifluoro-2-methyl-4'-nitro-m-propionotoluidide (flutamide) was given to 3 men. Analysis of plasma, urine and feces shows flutamide is rapidly and completely absorbed and excreted mainly through the kidneys. Analysis of plasma radioactivity shows flutamide is rapidly and extensively metabolized--only 2.5% of plasma radioactivity 1 h after dosing is associated with flutamide. At least 10 other metabolites are present, of which 6 have been tentatively identified. These are alpha,alpha,alpha-trifluoro-4'-amino-m-acetotoluidide (A); alpha,alpha,alpha-trifluoro-4'-amino-2-methyl-m-lactotoluidede (B); alpha,alpha,alpha-trifluoro-4'-nitro-m-acetotoluidede (C); alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide (D); alpha,alpha,alpha-trifluoro-4'-amino-2-methyl-m-propionotoluidide (E); and alpha,alpha,alpha-trifluoro-6-nitro-m-toluidine (F). (D) represents 23% of plasma tritium 1 h after drug and is a major metabolite at all other measured times. Each of the other metabolites accounts for less than 10% of plasma radioactivity. Minor amounts of flutamide and (A) through (F) are found in 0-24-h urine. An additional metabolite, alpha,alpha,alpha-trifluoro-2-amino-5-nitro-p-cresol, constitutes 25% of urine tritium. The rapid conversion of flutamide to (D) and the high plasma levels of (D) suggest (D) might be the active form of flutamide.

This article has been cited by other articles:

				P. Kang, D. Dalvie, E. Smith, S. Zhou, A. Deese, and J. A. Nieman Bioactivation of Flutamide Metabolites by Human Liver Microsomes Drug Metab. Dispos., July 1, 2008; 36(7): 1425 - 1437. [Abstract] [Full Text] [PDF]

				P. Kang, D. Dalvie, E. Smith, S. Zhou, and A. Deese Identification of a Novel Glutathione Conjugate of Flutamide in Incubations with Human Liver Microsomes Drug Metab. Dispos., July 1, 2007; 35(7): 1081 - 1088. [Abstract] [Full Text] [PDF]

				A. Tevell, H. Lennernas, M. Jonsson, M. Norlin, B. Lennernas, U. Bondesson, and M. Hedeland FLUTAMIDE METABOLISM IN FOUR DIFFERENT SPECIES IN VITRO AND IDENTIFICATION OF FLUTAMIDE METABOLITES IN HUMAN PATIENT URINE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY Drug Metab. Dispos., June 1, 2006; 34(6): 984 - 992. [Abstract] [Full Text] [PDF]

				W. Gao, Z. Wu, C. E. Bohl, J. Yang, D. D. Miller, and J. T. Dalton CHARACTERIZATION OF THE IN VITRO METABOLISM OF SELECTIVE ANDROGEN RECEPTOR MODULATOR USING HUMAN, RAT, AND DOG LIVER ENZYME PREPARATIONS Drug Metab. Dispos., February 1, 2006; 34(2): 243 - 253. [Abstract] [Full Text] [PDF]

				P. Farla, R. Hersmus, J. Trapman, and A. B. Houtsmuller Antiandrogens prevent stable DNA-binding of the androgen receptor J. Cell Sci., September 15, 2005; 118(18): 4187 - 4198. [Abstract] [Full Text] [PDF]

				M. Hero, O. A. Janne, K. Nanto-Salonen, L. Dunkel, and T. Raivio Circulating Antiandrogenic Activity in Children with Congenital Adrenal Hyperplasia during Peroral Flutamide Treatment J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5141 - 5145. [Abstract] [Full Text] [PDF]

				M. J. Grzywacz, J.-M. Yang, and W. N. Hait Effect of the Multidrug Resistance Protein on the Transport of the Antiandrogen Flutamide Cancer Res., May 15, 2003; 63(10): 2492 - 2498. [Abstract] [Full Text] [PDF]

				T. Gao and M. J. McPhaul Functional Activities of the A and B Forms of the Human Androgen Receptor in Response to Androgen Receptor Agonists and Antagonists Mol. Endocrinol., May 1, 1998; 12(5): 654 - 663. [Abstract] [Full Text]

				M. S. Shet, M. McPhaul, C. W. Fisher, N. R. Stallings, and R. W. Estabrook Metabolism of the Antiandrogenic Drug (Flutamide) by Human CYP1A2 Drug Metab. Dispos., November 1, 1997; 25(11): 1298 - 1303. [Abstract] [Full Text]